Primary immune deficiency diseases (PIDDs) are rare, difficult-to-manage disorders caused by inherited defects in cells of the immune system . They can result in increased risk of life-threatening infections, autoimmune diseases, and tumors . Understanding the molecular mechanisms underlying these immunodeficiencies is crucial to therapeutic decision-making and effective management of each disease.
For more than 30 years, IRP investigators at the National Institute of Allergy and Infectious Diseases (NIAID) have studied and developed new treatments for known PIDDs and worked to decipher immunodeficiencies of unknown etiology. In the last few years alone, IRP scientists identified:
IRP researchers and their collaborators have made significant contributions to current understanding of PIDDs and to the treatment of patients affected by these devastating diseases. In 2007, NIAID opened a Primary Immune Deficiency Clinic at the NIH Clinical Center to provide a focus of IRP expertise for referring physicians and their patients. The clinic accepts patients with known or suspected PIDDs and offers treatment recommendations and, in some cases, a disease diagnosis.
Press Release – NIAID Initiative Addresses Primary Immune Deficiency Diseases: http://www.niaid.nih.gov/news/newsreleases/2003/Pages/pirc.aspx.
Jain A, Ma CA, Liu S, Brown M, Cohen J, Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol. 2001 Mar;2(3):223-8.
Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, Matthews HF, Davis J, Turner ML, Uzel G, Holland SM, Su HC. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009 Nov 19;361(21):2046-55.